If you suffer from obesity, a recent study reveals which of the two drugs will help you lose a greater amount of weight? Mounjaro or Ozempic.
The study was conducted by researchers from Truvita Research Company in the United States, and was published on the MedArchiv website, and has not yet been subject to peer review.
The study found that people who were overweight or obese lost more weight and faster using Monjaro, compared to Ozempic.
Within one year of starting treatment, 42.3% of those who took Tirzepatide, the active ingredient in Mongaro and Zepbound, lost at least 15% of their body weight, compared to 19.3% among patients who took Semaglutide. (semaglutide), the main ingredient in Wegovy and Ozempic.
Monjaro
Patients taking Monjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than 3 times as likely to lose at least 15%, compared to patients taking Ozempic. “.
The researchers used electronic health records and pharmacy dispensing data to analyze weight loss trajectories in 9,193 patients receiving Monjaro and the same number of patients receiving Ozempic. The average weight of the participant was 110 kilograms, and almost half of them suffered from type 2 diabetes.
The study also found that after 3 months of treatment, patients who took Monjaro lost an average of 2.3% more weight than those who took Ozempic. After 6 months, the difference widened to 4.3%, and by 12 months, the Monjaro group had lost 7.2% more weight on average.
“This study can help inform patient care and outcomes today, not months from now,” said Dr. Nick Stuckey, study author and vice president of TruVita Research.
The researchers found that patients without type 2 diabetes lost more weight than those with the condition, but the differences in effectiveness between Mongaro and Ozempic were similar in both groups.
The difference between Mongaro and Ozimbek
Monjaro and Ozempic are weekly injections that change the way patients eat and cause decreased appetite by mimicking certain hormones in the gut.
Ozempic and Wijovi only mimic one hormone that regulates hunger called glucagon-like peptide-1, also known as GLP-1, which increases feelings of fullness and lowers blood sugar levels.
In contrast, Monjaro and Zibond mimic glucagon-like peptide-1 and another hormone in the gut called glucose-dependent insulinopolypeptide, or GIP, meaning they mimic two hormones.
The dual approach means Monjaro and Zibond have an enhanced effect on regulating appetite and blood sugar levels, which some experts say may lead to greater weight loss than drugs targeting glucagon-like peptide alone.
2023-12-03 15:20:27
#lose #weight #quickly #Mongaro #Ozambik #health
